Molecular Cancer Therapeutics  Bridging the Lab and the Clinic in Cancer Medicine
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Nyåkern, M.
Right arrow Articles by Martelli, A. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Nyåkern, M.
Right arrow Articles by Martelli, A. M.
Mol Cancer Ther. 2006;5:1559-1570
© 2006 American Association for Cancer Research

Research Articles: Therapeutics

Synergistic induction of apoptosis in human leukemia T cells by the Akt inhibitor perifosine and etoposide through activation of intrinsic and Fas-mediated extrinsic cell death pathways

Maria Nyåkern1, Alessandra Cappellini3, Irina Mantovani1 and Alberto M. Martelli1,2

1 Dipartimento di Scienze Anatomiche Umane e Fisiopatologia dell'Apparato Locomotore, Sezione di Anatomia, Cell Signalling Laboratory, Università di Bologna; 2 Istituto per i Trapianti d'Organo e l'Immunocitologia del Consiglio Nazionale delle Ricerche, Sezione di Bologna c/o Instituto Ortopedico Rizzoli, Bologna, Italy; and 3 Dipartimento di Scienze Motorie e della Salute, Sezione di Anatomia, Università di Cassino, Cassino, Italy

Requests for reprints: Alberto M. Martelli, Dipartimento di Scienze Anatomiche Umane e Fisiopatologia dell'Apparato Locomotore, Università di Bologna, via Irnerio 48, 40126 Bologna, Italy. Phone: 39-512091580; Fax: 39-512091695. E-mail: amartell{at}biocfarm.unibo.it

Perifosine is an Akt inhibitor displaying strong antineoplastic effects in human tumor cell lines and is currently being tested in phase II clinical trials for treatment of major human cancers. Several recent studies showed the apoptotic effect of perifosine alone or in combination with other anticancer agents. However, this is the first study describing the effects of combining perifosine with the commonly used chemotherapy drug etoposide in cultured human Jurkat T-leukemia cells. Low concentrations of perifosine (5 µmol/L) induced cell death in a synergistic fashion with etoposide if used simultaneously or immediately following exposure to etoposide (posttreatment). The increase in cell death seems to be due to an inactivation of the Akt survival pathway, where treated cells showed a complete dephosphorylation of Akt. Moreover, combined drug-induced Akt deactivation was associated with a parallel decrease in phosphorylation of FoxO1 transcription factor and in expression of antiapoptotic Bcl-xL. Furthermore, the increase in cell death was associated with a specific activation of the caspase-dependent Fas death receptor pathway. These findings might be useful when designing clinical trials where chemotherapy is combined with perifosine for a potential broad use against hematologic malignancies in which the Akt survival pathway is frequently activated. [Mol Cancer Ther 2006;5(6):1559–70]


Grant support: Associazione Italiana Ricerca sul Cancro (Regional Grants), Italian Ministero dell’Istruzione, Università e Ricerca Fondo per gli Investimenti della Ricerca di Base 2001, and Fondazione del Monte di Bologna e Ravenna.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received 2/ 9/06; revised 4/ 5/06; accepted 4/21/06.




This article has been cited by other articles:


Home page
Mol. Pharmacol.Home page
F. Fala, W. L. Blalock, P. L. Tazzari, A. Cappellini, F. Chiarini, G. Martinelli, A. Tafuri, J. A. McCubrey, L. Cocco, and A. M. Martelli
Proapoptotic Activity and Chemosensitizing Effect of the Novel Akt Inhibitor (2S)-1-(1H-Indol-3-yl)-3-[5-(3-methyl-2H-indazol-5-yl)pyridin-3-yl]oxypropan2-amine (A443654) in T-Cell Acute Lymphoblastic Leukemia
Mol. Pharmacol., September 1, 2008; 74(3): 884 - 895.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
E. David, R. Sinha, J. Chen, S.-Y. Sun, J. L. Kaufman, and S. Lonial
Perifosine Synergistically Enhances TRAIL-Induced Myeloma Cell Apoptosis via Up-Regulation of Death Receptors
Clin. Cancer Res., August 15, 2008; 14(16): 5090 - 5098.
[Abstract] [Full Text] [PDF]


Home page
aacredbookHome page
P. A Dennis
Targeting Akt in Cancer: Promise, Progress, and Potential Pitfalls
Am. Assoc. Cancer Res. Educ. Book, April 12, 2008; 2008(1): 25 - 35.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
A. H. van der Luit, S. R. Vink, J. B. Klarenbeek, D. Perrissoud, E. Solary, M. Verheij, and W. J. van Blitterswijk
A new class of anticancer alkylphospholipids uses lipid rafts as membrane gateways to induce apoptosis in lymphoma cells
Mol. Cancer Ther., August 1, 2007; 6(8): 2337 - 2345.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
H. A. Elrod, Y.-D. Lin, P. Yue, X. Wang, S. Lonial, F. R. Khuri, and S.-Y. Sun
The alkylphospholipid perifosine induces apoptosis of human lung cancer cells requiring inhibition of Akt and activation of the extrinsic apoptotic pathway
Mol. Cancer Ther., July 1, 2007; 6(7): 2029 - 2038.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
K. Behbakht, L. Qamar, C. S. Aldridge, R. D. Coletta, S. A. Davidson, A. Thorburn, and H. L. Ford
Six1 Overexpression in Ovarian Carcinoma Causes Resistance to TRAIL-Mediated Apoptosis and Is Associated with Poor Survival
Cancer Res., April 1, 2007; 67(7): 3036 - 3042.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2006 by the American Association for Cancer Research.